Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade

Reference:
Size

,

Brand

Product type

Clonality

Expression system

Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade

Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade

General information about Bevacizumab

Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.

Product nameBevacizumab Biosimilar - Anti-VEGF mAb - Research Grade
SourceDrugBank DB00112
SpeciesHuman
Molecular weight149kDa
Purity>90%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsBevacizumab
ReferencePX-TA1006
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1
ClonalityMonoclonal Antibody
SourceDrugBank DB00112
Product nameBevacizumab Biosimilar - Anti-VEGF mAb - Research Grade
SourceDrugBank DB00112
SpeciesHuman
Expression systemMammalian cells
Molecular weight149kDa
Purity>90%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsBevacizumab
ReferencePX-TA1006
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1
ClonalityMonoclonal Antibody
SourceDrugBank DB00112

Reviews

There are no reviews yet.

Be the first to review “Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade”

Your email address will not be published.


Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: